Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Biorec S.a.

Silvio Ernesto Perea Rodriguez

Boris Ernesto Acevedo Castro

Alicia Santos Savio

Osvaldo Reyes Acosta

Luis Javier González López

Lila Rosa Castellanos Serra

Daniel Fernando Alonso

Daniel Eduardo Gomez

Jeovanis Gil Valdés

Lázaro Hiram Betancourt Núñez

Haydee Geronimo Perez

Vladimir Besada Pérez

Jorge Fernández De Cossio Dorta Duque

Aniel Sánchez Puente

Yassel Ramos Gómez

Yasser Perera Negrin

Alexis Musacchio Lasa

Raimundo Ubieta Gómez

Ania Cabrales Rico

Roberto Vera Alvarez

Yaquelin Puchades Izaguirre

Nelson Francisco Santiago Vispo

Yuliet Mazola Reyes

Ania De La Nuez Veulens

Rolando Eduardo Rodriguez Fernandez

Arielis Rodríguez Ulloa

Yanelis Morera Diaz

Alejandro Moro Soria

Luis Javier Gonzalez Lopez

Ricardo Silva Rodriguez

Belkis González Barrios

Belkis Gonzalez Barrios

Jose Rafael Martinez Castillo

Armando Alexei Rodriquez Alfonso

Arielis Rodriguez Ulloa

Celia Aurora Arrieta Aguero

Yaquelín Puchades Izaguirre

Raimundo Ubieta GÓMEZ

Vladimir Besada Perez

Jorge Fernandez De Cossio Dorta Duque

Lazaro Hiram Betancourt Nunez

Yassel Ramos Gomez

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.

Antineoplastic compounds and pharmaceutical compositions thereof

Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.

Vaccine composition comprising interleukin-15 (IL-15)

Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15R&#x3b1;) and TNF&#x3b1;-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R&#x3b1; expression is associated to the disease progression.

Interleukin-15 antagonist peptide

This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.

Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors

Growing community of inventors

Ciudad de la Habana, Cuba

Silvio Ernesto Perea Rodriguez